Analytical Data
-
Gene name
MIOX
- Application
-
Alternative Names
ALDRL6; KSP32; RSOR; Kidney-Specific Protein 32; Aldehyde Reductase(Aldose Reductase)Like 6; Renal-specific oxidoreductase; Myo-inositol oxygenase
-
Species
Human
-
Source
E. coli
-
Tag
Two N- s, His- & SUMO-
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9UGB7
-
Expression Region
Met1~Trp285
-
Molecular Weight
46kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MIOX (myo-inositol oxygenase) is an enzyme that plays a critical role in the metabolism of inositol, a vital sugar alcohol that contributes to various cellular processes, including cell signaling, osmoregulation, and the synthesis of phospholipids. Research on MIOX has gained momentum in recent years due to its significance in both physiological and pathological contexts. Dysregulation of inositol metabolism is implicated in several diseases, including diabetes, neurodegenerative disorders, and certain cancers. The recombinant expression of MIOX has emerged as a crucial approach to study its enzymatic properties, regulatory mechanisms, and functional roles in various cellular contexts. By producing MIOX through recombinant techniques, researchers can obtain large quantities of the enzyme for detailed biochemical assays and structural studies, which are essential for understanding its catalytic mechanisms and interactions with substrates. Furthermore, investigating MIOX in the context of disease models can provide insights into its potential as a therapeutic target. As we expand our knowledge of MIOX and its biological implications, the enzyme may reveal novel avenues for intervention in metabolic diseases and other disorders associated with aberrant inositol metabolism.
